Herpes simplex virus vectors for gene therapy in Parkinson's disease and other diseases of the nervous system

Journal of the Royal Society of Medicine

Volumn 92, Issue 11, 1999, Pages 566-570

  Latchman, David S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NEUROTROPHIC FACTOR; TYROSINE 3 MONOOXYGENASE; VIRUS VECTOR;

DOPAMINERGIC NERVE CELL; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; MOTOR NEURON DISEASE; PARKINSON DISEASE; SHORT SURVEY; VIRUS GENOME;

EID: 0032724801     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1177/014107689909201107     Document Type: Short Survey

References (25)

1. 1 French Anderson W. Human gene therapy. Nature 1998;392(suppl): 25-30
2. 2 Haase G, Kennel P, Pettmann B, et al. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nature Med 1997;3:429-36
3. 3 Latchman DS. Heat shock proteins: protective effect and potential therapeutic use. Int J Molec Med 1998;2:375-81
4. 4 Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1996;247:574-77
5. 5 Bencsjcs C, Wachtel SR, Milstien S, et al. Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of 1. DOPA by primary fibroblasts. J. Neurosci 1996;16:4449-56
6. 6 Lapchak PA, Miller PJ, Jiao SS, Araujo DM, Hilt D, Collins R. Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease. Neurodegeneration 1996;5:197-205
7. 7 Lapchak PA. Therapeutic potentials for glial cell line derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. Rev Neurosci 1996;7:165-76
8. 8 Latchman DS, ed. Genetic Manipulation of the Nervous System. London: Academic Press, 1996
9. 9 Fisher LJ, Jinnah HA, Kale LC, Higgins GA, Gage FH. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron 1991;6:371-80
10. 10 Senut M-C, Subr ST, Gage FH. Transplantation of genetically modified non-neuronal cells in the central nervous system. In: Latchman DS, ed. Genetic Manipulation of the Nervous System. London: Academic Press, 1996:181-202
11. 11 Tsuda M, Imaokea T. Direct injection of plasmid DNA into the brain. In: Latchman DS, ed. Genetic Manipulation of the Nervous System. London: Academic Press, 1996:235-48
12. 12 Horellou P, Vigne E, Castel MN, et al. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. NeuroReport 1994;6:49-53
13. 13 Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nature Genet 1994;8:148-54
14. 14 During MJ, Naegele JR, O'Malley KL, Geller AI. Long-term behavioural recovery in parkinsonian rats by an HSV vector expressing tyrosine hydoxylase. Science 1994;266:1199-403
15. 15 Latchman DS. Molecular biology of herpes simplex virus latency. Int J Exp Pathol 1990;71:133-41
16. 16 Fink DJ, DeLuca NA, Goins WF, Giorioso JC. Gene transfer to neurons using herpes simplex virus-based vectors. Ann Rev Neurosci 1996;19:265-87
17. 17 Coffin RS, Latchman DS. Herpes simplex virus based vectors. In: Latchman DS, ed. Genetic Manipulation of the Nervous System. London: Academic Press, 1996:99-114
18. 18 Dobson AT, Margolis TP, Sedarati F, Stevens JG, Feldman UT. A latent nonpathogenic HSV-1 derived vector stably expresses β galactosidase in mouse neurons. Neuton 1990;5:353-60
19. 19 Howard MK, Kershaw T, Gibb B, et al. High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5, Gene Ther 1998; 5:1137-47
20. 20 Maclean AR, Fareed MU, Robertson L, Harland J, Brown SM. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence related sequenes in Glasgow strain 17+ between immediate-early gene 1 and the 'a' sequence. J Gen Virol 1991;72:631 -9
21. 21 Coffin RS, Maclean AR, Latchman HS, Brown SM. Gene delivery to the central and peripheral nervous systems of mice using HSV 1 ICP 34.5 deletion mutant vectors. Gene Ther 1996;3:886-91
22. 22 Wang Q, Guo J, Jia W. Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1. Gene Ther 1997;4:1300-4
23. 23 Rampling R, Cruickshank G, Maclean AR, Brown SM. Therapeutic replication competent herpes virus. Nature Med 1999;2:133
24. 24 Wagstaff MJD, Collaco-Moraes Y, Smith J, de Belleroche J, Coffin RS, Latchman DS. Protection of neuronal cells from apoptosis by hsp27 delivered with a herpes simplex virus-based vector. J Biol Chem 1999;274:5061-9
25. 25 Smith MD, Ensor EA, Coffin RS, Boxer LM, Latchman DS. Bel-2 transcription from the proximal p2 promoter is activated in neuronal cells by the Brn-3a POU family transciption factor. J Biol Chemistry 1998;273:16715-22